{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T23:38:48Z","timestamp":1790379528480,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Intensiva"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.medin.2017.08.009","type":"journal-article","created":{"date-parts":[[2017,11,7]],"date-time":"2017-11-07T10:15:12Z","timestamp":1510049712000},"page":"409-415","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Levosimendan in patients with cardiogenic shock complicating myocardial infarction: A meta-analysis"],"prefix":"10.1016","volume":"42","author":[{"given":"M.","family":"Fang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medin.2017.08.009_bib0175","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1001\/jama.297.17.1892","article-title":"Decline in rates of death and heart failure in acute coronary syndromes, 1999\u20132006","volume":"297","author":"Fox","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.medin.2017.08.009_bib0180","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1208410","article-title":"IABP-SHOCK II Trial Investigators: intraaortic balloon support for myocardial infarction with cardiogenic shock","volume":"367","author":"Thiele","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medin.2017.08.009_bib0185","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.5603\/KP.a2016.0087","article-title":"Experience in application of therapies VA ECMO as short-term mechanical support of circulatory system of adult patients in cardiogenic shock","volume":"74","author":"Musial","year":"2016","journal-title":"Kardiol Pol"},{"key":"10.1016\/j.medin.2017.08.009_bib0190","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1097\/00000542-200603000-00024","article-title":"Levosimendan a new inotropic and vasodilator agent","volume":"104","author":"Toller","year":"2006","journal-title":"Anesthesiology"},{"key":"10.1016\/j.medin.2017.08.009_bib0195","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1023\/B:MCBI.0000049141.37823.19","article-title":"The contractile apparatus as a target for drugs against heart failure: interaction of levosimendan, a calcium sensitiser, with cardiac troponin c","volume":"266","author":"Sorsa","year":"2004","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.medin.2017.08.009_bib0200","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1527-3466.2005.tb00158.x","article-title":"Pharmacological mechanisms contributing to the clinical efficacy of levosimendan","volume":"23","author":"Papp","year":"2005","journal-title":"Cardiovasc Drug Rev"},{"key":"10.1016\/j.medin.2017.08.009_bib0205","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1093\/bja\/aeu446","article-title":"A Bayesian network meta-analysis on the effect of inodilatatory agents on mortality","volume":"114","author":"Greco","year":"2015","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.medin.2017.08.009_bib0210","series-title":"Cochrane handbook for systematic reviews of interventions. Version 5. The cochrane collaboration, 2011","author":"Higgins","year":"2011"},{"key":"10.1016\/j.medin.2017.08.009_bib0215","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle\u2013Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.medin.2017.08.009_bib0220","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1097\/CCM.0b013e3181809846","article-title":"Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction","volume":"36","author":"Fuhrmann","year":"2008","journal-title":"Crit Care Med"},{"key":"10.1016\/j.medin.2017.08.009_bib0225","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/eurjhf\/hfs215","article-title":"Levosimendan in acute heart failure following primary percutaneous coronary intervention treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study","volume":"15","author":"Husebye","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.medin.2017.08.009_bib0230","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ijcard.2007.04.143","article-title":"Effects of levsimendan versus dobutamine on long-term survival of patients with cardiogenic shock after primary coronary angioplasty","volume":"127","author":"Samimi-Fard","year":"2008","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.medin.2017.08.009_bib0235","first-page":"46","article-title":"Levosimendan for treating acute myocardial infarction complicated by cardiogenic shock in 54 cases","volume":"9","author":"Peng","year":"2015","journal-title":"China Pharm"},{"key":"10.1016\/j.medin.2017.08.009_bib0240","unstructured":"\u7f57\u6bc5, \u5218\u8def\u57f9, \u6768\u632f\u5b87\u7b49\u3002\u5de6\u897f\u5b5f\u65e6\u5bf9\u6025\u6027\u5fc3\u808c\u6897\u6b7b\u5e76\u53d1\u5fc3\u6e90\u6027\u4f11\u514b\u60a3\u8005\u7684\u7597\u6548\u3002\u5b9e\u7528\u533b\u5b66\u6742\u5fd72013; \u7b2c29\u537719\u671f: 3229\u201330."},{"key":"10.1016\/j.medin.2017.08.009_bib0245","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/MAT.0b013e3182a4b32e","article-title":"Levosimendan may improve weaning outcomes in venoarterial ECMO patients","volume":"59","author":"Affronti","year":"2013","journal-title":"ASAIO J"},{"key":"10.1016\/j.medin.2017.08.009_bib0250","doi-asserted-by":"crossref","first-page":"657","DOI":"10.2147\/VHRM.S8856","article-title":"Levosimendan neither improves nor worsens mortality in patients with cardiogenic shock due to ST-elevation myocardial infarction","volume":"7","author":"Omerovic","year":"2010","journal-title":"Vasc Health Risk Manage"},{"key":"10.1016\/j.medin.2017.08.009_bib0255","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/17482940701358564","article-title":"Early and sustained haemodynamic improvement with levosimendan compared to intraaortic balloon counterpulsation (IABP) in cardiogenic shock complicating acute myocardial infarction","volume":"10","author":"Christoph","year":"2008","journal-title":"Acute Cardiac Care"},{"issue":"Suppl. 1","key":"10.1016\/j.medin.2017.08.009_bib0260","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/cc7336","article-title":"Levosimendan therapy does not improve survival of post-resuscitation cardiogenic shock patients","volume":"13","author":"Soos","year":"2009","journal-title":"Crit Care"},{"issue":"Suppl. 1","key":"10.1016\/j.medin.2017.08.009_bib0265","first-page":"S39","article-title":"Mixed venous oxygen saturation. Its role in the assessment of patients developing after ST-elevation myocardial infarction (STEMI)","volume":"5","author":"Poli","year":"2011","journal-title":"Giornale Italiano di Cardiologia"},{"issue":"Suppl. 1","key":"10.1016\/j.medin.2017.08.009_bib0270","first-page":"S28","article-title":"Cardiogenic shock in acute myocardial infarction: still looking for the best inotrope","volume":"1","author":"Caetano","year":"2012","journal-title":"Eur Heart J: Acute Cardiovasc Care"},{"issue":"Suppl.","key":"10.1016\/j.medin.2017.08.009_bib0275","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.resuscitation.2013.08.043","article-title":"Long term effects of levosimendan therapy in patients with cardiogenic shock","volume":"84","author":"Katsytadze","year":"2013","journal-title":"Resuscitation"},{"key":"10.1016\/j.medin.2017.08.009_bib0280","doi-asserted-by":"crossref","first-page":"E770","DOI":"10.1016\/S0735-1097(13)60770-6","article-title":"Hemodynamic improvement following levosimendan treatment in acute myocardial infraction complicated by cardiogenic shock patients treated with primary PCI and IABP","volume":"10","author":"Mancone","year":"2013","journal-title":"JACC"},{"key":"10.1016\/j.medin.2017.08.009_bib0285","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00134-014-3604-1","article-title":"Effects of levosimendan for low cardiac output syndrome in critically ill patients: systematic review with meta-analysis and trial sequential analysis","volume":"41","author":"Koster","year":"2015","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.medin.2017.08.009_bib0290","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/jocs.12562","article-title":"Levosimendan reduces mortality in adults with left ventricular dysfunction undergoing cardiac surgery: a systematic review and meta-analysis","volume":"30","author":"Lim","year":"2015","journal-title":"J Card Surg"},{"key":"10.1016\/j.medin.2017.08.009_bib0295","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1161\/CIRCULATIONAHA.105.542407","article-title":"Mechanisms and use of calcium-sensitizing agents in the failing heart","volume":"113","author":"Kass","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.medin.2017.08.009_bib0300","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ahj.2016.03.021","article-title":"A randomized controlled trial of levosimendan to reduce mortality in high-risk cardiac surgery patients (CHEETAH): rationale and design","volume":"177","author":"Zangrillo","year":"2016","journal-title":"Am Heart J"},{"key":"10.1016\/j.medin.2017.08.009_bib0305","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1161\/01.CIR.98.20.2141","article-title":"Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium","volume":"98","author":"Hasenfuss","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.medin.2017.08.009_bib0310","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S0009-9236(97)90139-9","article-title":"Myocardial efficiency during calcium sensitization with levosimendan: a noninvasive study with positron emission tomography and echocardiography in healthy volunteers","volume":"61","author":"Ukkonen","year":"1997","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.medin.2017.08.009_bib0315","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/00005344-200404000-00011","article-title":"Effects of levosimendan and milrinone on oxygen consumption in isolated guineapig heart","volume":"43","author":"Kaheinen","year":"2004","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.medin.2017.08.009_bib0320","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S0009-9236(97)90139-9","article-title":"Myocardial efficiency during calcium sensitization with levosimendan: a noninvasive study with positron emission tomography and echocardiography in healthy volunteers","volume":"61","author":"Ukkonen","year":"1997","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.medin.2017.08.009_bib0325","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1067\/mcp.2000.110972","article-title":"Myocardial efficiency during levosimendan infusion in congestive heart failure","volume":"68","author":"Ukkonen","year":"2000","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl. A","key":"10.1016\/j.medin.2017.08.009_bib0330","doi-asserted-by":"crossref","first-page":"191A","DOI":"10.1016\/S0735-1097(04)90812-1","article-title":"Levosimendan is safe and effective in patients with severe low cardiac output heart failure and critical hypotension","volume":"43","author":"Franco","year":"2004","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl. 1","key":"10.1016\/j.medin.2017.08.009_bib0335","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/cc2550","article-title":"Efficacy of levosimendan in shock. (Abstract)","volume":"8","author":"McLean","year":"2004","journal-title":"Crit Care"}],"container-title":["Medicina Intensiva"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210569117302838?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210569117302838?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,5]],"date-time":"2019-10-05T15:28:31Z","timestamp":1570289311000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0210569117302838"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S0210569117302838"],"URL":"https:\/\/doi.org\/10.1016\/j.medin.2017.08.009","relation":{},"ISSN":["0210-5691"],"issn-type":[{"value":"0210-5691","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Levosimendan in patients with cardiogenic shock complicating myocardial infarction: A meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Medicina Intensiva","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medin.2017.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Espa\u00f1a, S.L.U. y SEMICYUC. All rights reserved.","name":"copyright","label":"Copyright"}]}}